Mount Tam Biotechnologies, Inc.,
and Isomerase Therapeutics Announce Expansion of Their Collaboration to Discover and Develop Novel Rapalogs
NOVATO, CA - (January 9, 2017) - Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM) is pleased to announce that Mount Tam and Cambridge, UK-based Isomerase Therapeutics Ltd (“Isomerase”) have agreed to expand their research collaboration for the discovery and development of novel rapalogs in 2017. As part of this research collaboration, Mount Tam will work to characterize and advance discovery programs for a range of novel and proprietary rapalogs that have been developed through Isomerase’s proprietary approach to improving microbial natural products via their unique biosynthetic medicinal chemistry platform.
The ultimate goal of this collaboration is to discover and develop differentiated mTOR modulators that can improve upon currently marketed rapalogs and further strengthen Mount Tam’s current portfolio of proprietary compounds. Richard Marshak, Mount Tam’s CEO, said “We are excited by the opportunity to work with these novel rapalogs given the great potential for mTOR modulators to address a wide range of serious unmet medical needs across a range of therapeutic areas where satisfactory treatments are lacking. It is also rewarding to advance our collaboration with the team at Isomerase, one of the world’s leaders in advancing microbial natural products”.